This article reviews the use of real-world evidence (RWE) from observational studies to evaluate herpes zoster vaccine effectiveness and complement clinical trial data that have known limitations. The use of RWE with appropriate study designs and cautious interpretation can be informative in decision-making. Understanding the advantages and limitations of studies yielding RWE can facilitate the critical evaluation of findings from different studies. This is a timely issue, as regulatory agencies are considering how RWE can contribute to the assessment of effectiveness in regulatory decision-making.
Before a potential herpes zoster (HZ) vaccine can be considered for licensure, vaccine manufacturers are required to demonstrate vaccine efficacy by conducting a large-scale randomized, controlled trial (RCT). The currently licensed HZ vaccines are a live virus vaccine (hereafter, "zoster vaccine live" [Zostavax] ) [1] and the recombinant zoster vaccine (RZV [Shingrix] ) [2] that requires a 2-dose regimen. Although RCTs are considered the gold standard for causal inference, they have substantial limitations and cannot answer many critical questions. In this article, we review the use of real-world evidence to evaluate HZ vaccine effectiveness and complement RCT data.
RCT ADVANTAGES AND LIMITATIONS
RCTs provide the critical evidence of efficacy and safety needed for vaccine licensure. Randomization with a sufficient number of subjects can ensure that any extraneous factors that could affect HZ risk are equally distributed between the vaccinated and unvaccinated groups. Randomization not only guarantees the highest level of internal validity, but also establishes the mathematical foundation for causal inference. Many probabilistic inferential statistics, such as P values, confidence intervals, and likelihood ratios, have very limited meaning when the mechanism for exposure assignment is largely unknown or is known to be nonrandom [3] . Randomization thus offers the ability to isolate the observed effect of a vaccine and to make causal inferences. There are other advantages of RCTs, including having greater homogeneity among participants, having a consistent case definition and ascertainment approach, and having ideal settings for storage and handling of vaccines and vaccine administration.
However, there are limitations associated with RCTs. The first is the generalizability of the study population (ie, external validity). In a real-world situation, HZ vaccine is given to a physiologically and medically heterogenous elderly population. How heterogeneity affects the protective effects observed in a RCT with a selected population is unknown. The Shingles Prevention Study of zoster vaccine live enrolled a highly motivated population (38 546 adults ≥ 60 years old) that was 40% female and just 2% African American and 1.4% Hispanic. Study participants were healthy, ambulatory, and required a history of varicella or >30 years of residence in the United States. Patients with immunocompromising conditions were excluded. Persons with prior HZ were excluded [4] . The RCTs for RZV, which enrolled 15 411 participants ≥50 years old and 13 900 participants ≥70 years old, had a similar list of exclusion criteria that have implications for generalizability [5, 6] .
The next consideration relates to the procedure for HZ outcome ascertainment. In the RCTs, vigorous active case finding was conducted to identify even the mildest cases of HZ, whether or not the patients with such cases would have sought medical attention. In a real-world setting, the most clinically relevant HZ cases are those for which patients decide to seek medical attention.
The third consideration is vaccine handling and storage and administration practice. For example, zoster vaccine live must be kept frozen at <5°F and administered within 30 minutes of reconstitution. The challenges of maintaining a cold chain are considerable. Receipt of zoster vaccine live compromised by temperature deviations is possible in routine practice. RZV is licensed as a 2-dose series administered 2 months apart. It must be stored in the refrigerator and should be administered immediately after reconstitution or stored in the refrigerator and used within 6 hours. It should be discarded if it has been frozen. There will certainly be deviation from these recommended intervals and conditions in a real-world setting. How this would affect the vaccine's protective effect remains unknown.
Finally, from a safety perspective, RCTs usually include limited numbers of homogeneous healthy participants, constraining RCTs' ability to detect very rare adverse events. In contrast, after vaccines are licensed and given to millions of individuals, observational studies using real-world data have the ability to detect very rare adverse events in more heterogeneous populations [7] . Some previous experiences, such as an increased risk of Guillain-Barre syndrome among recipients of 1976 swine-influenza vaccine or 2009 pandemic influenza A(H1N1) monovalent influenza vaccine [8] , an increased risk of intussusception in infants after the first developed rotavirus vaccine (Rotashield) in 1999 [9] , or an increased risk of severe dengue disease after dengue vaccine receipt among children from the Philippines who had never been exposed to the virus [10] , have clearly exemplified the limitation of RCTs in evaluating vaccine safety.
REAL-WORLD STUDIES
Given these substantial limitations and the high costs of conducting a large RCT, observational studies in a real-world setting can serve as a useful complement. A recent publication from Sherman et al suggests the value of using real-world evidence as an important tool in evaluating effectiveness [11] . They define real-world evidence as "information on health care derived from multiple sources outside typical clinical research settings, including electronic health records [EHRs], claims and billing data, product and disease registries, and data gathered through personal devices and health applications" [11] (p. 2293). A broader definition of real-world evidence could also include data collected from observational studies involving study-specific data collection activities. However, the authors also raise concerns about the unknown quality of the data collected from real-world settings, the use of commonly available analytic tools without fully understanding the study design issues and statistical assumptions behind the analyses, and the lack of savvy personnel to appropriately interpret the study results [11] . The need for well-designed, well-executed, and well-analyzed observational studies and for analytic methods for controlling imbalance between comparison groups in such studies have been highlighted in other recent publications [12, 13] .
Some considerations for designing and interpreting realworld vaccine effectiveness (VE) studies for HZ vaccines deserve attention.
Confounding
In all observational studies, risk factors for the outcome (ie, HZ) that are differentially distributed between the vaccinated and unvaccinated groups need to be evaluated. For example, because vaccine uptake and the risk of HZ are lower among African Americans [14, 15] , race could be a potential confounder in the estimation of VE. Therefore, an imbalance in racial composition between the vaccinated and unvaccinated groups could potentially generate bias. Also, there has been inconclusive evidence about the association between one's risk of developing HZ and their family history of HZ [16] [17] [18] [19] ; if persons with a family history were more aware of HZ and more likely to receive the vaccine, it would result in an observed higher risk in the vaccinated population. A prior personal history of HZ could also confound VE estimates if individuals with such a history were more likely to receive the vaccine. This could become more significant when RZV becomes available and more individuals with a history of HZ consider getting vaccinated. We could control for a prior history of HZ or perform a stratified analysis by this variable. Frailty, which is considered an important confounder for the VE estimation of influenza vaccine, might also confound the VE estimation for HZ vaccine. Frailty might also determine the likelihood of vaccination or of responding to the vaccine. Measuring frailty has been challenging in the elderly population and is even more complex when using data collected through health insurance claims or EHRs. The relevant indicators for frailty in a VE study for HZ vaccine might not be apparent.
In our previous study that evaluated the VE of zoster vaccine live, the unadjusted hazard ratio (HR) and the adjusted HR were very close (0.49 vs 0.45) [14] . Similar close unadjusted and adjusted HRs were also observed in our other studies, although the study populations were different (eg, patients with end-stage renal disease or after chemotherapy) [20, 21] . Langan et al also reported very small differences between the unadjusted and adjusted HRs in both main analyses and analyses stratified by immunosuppression status, although their study design and adjusted covariates were different from ours [22] . These observations suggest that either the distribution of potential risk factors for HZ between the vaccinated and unvaccinated groups is reasonably comparable or the positive and negative confounding cancel each other out.
There are many ways to control for imbalance between the vaccinated and the unvaccinated groups. In the design stage, we can restrict the subjects and match the 2 groups on important confounding factors. In the analysis stage, we can perform stratified analysis, multivariate analysis, propensity score adjusted analysis, or instrumental variable analysis. Knowing the potential confounders and evaluating whether there is an acceptable measure of these variables are essential. In many instances, we might not have an ideal measure of these variables. This could be problematic when using an existing data set in which the needed information is not readily collected, such as functional status or daily activity level as a proxy for frailty. Understanding this limitation, the interpretation of VE statistics could involve phrases like "If the exposure [vaccine] In studies using EHR or health insurance claims-based data, HZ outcomes are obtained from clinical encounters. Bias can arise if healthcare-seeking behavior or access to care is different between the vaccinated and unvaccinated groups. For example, it is possible that the vaccinated group has better access to care and is more likely to seek care for HZ. In our previous studies, we tried to account for this difference between the vaccinated and unvaccinated groups by controlling for utilization history. Utilization history can be an indicator for healthcare-seeking behavior and can also be a proxy for general health status. The vaccinated group tended to have a higher number of outpatient visits but a smaller number of emergency department and inpatient visits in the year prior to follow-up, suggesting that they could be healthier overall. Healthcare-seeking behavior and access to care would affect compliance with the 2-dose regimen of RZV, since individuals who comply with the 2-dose regimen within the recommended interval are more likely to have better access to care and to seek care more often. This could potentially lead to underestimation of VE if the difference is not accounted for. A study by Hales et al estimated that approximately 90% of patients aged ≥55 years with HZ sought care for HZ [23] . A high frequency of care-seeking behavior among individuals with HZ can minimize the bias due to differential healthcare-seeking behavior or access to care.
Understanding the influence of healthcare-seeking behavior and access to care on VE becomes more complicated when assessing the VE against postherpetic neuralgia (PHN), a complication of HZ involving chronic pain. We conducted a study in which we collected information from prospectively identified patients with laboratory-confirmed HZ. We asked the patients at 90 days after diagnosis about their HZ-related pain, using the Zoster Brief Pain Inventory (ZBPI) [24] . On the basis of the ZBPI 10-point scale, we classified pain within the past 24 hours as PHN as a self-reported pain score of ≥3. We then compared the self-reported results with encounter records 90-180 days after diagnosis, to assess whether they sought care for HZ-related pain during that period. The results were surprising: only 36.4% of women and 22.5% of men who reported persistent HZ-related pain sought care for it and, therefore, would have been detected during review of the encounter records. Therefore, when we used self-reported pain as the measure of PHN, the frequency of PHN in the unvaccinated group was 14.4%, compared with 8.6% in the vaccinated group. When we used encounter records as the measure of PHN, the frequency of PHN in the unvaccinated was 9.2%, as compared to 5.0% in the vaccinated group. Different approaches and differential severity may partly explain the difference between self-reported PHN and healthcare encounters for treatment of PHN. This finding indicates the complexity of interpreting the VE against PHN, because the incidence of the outcome is measure dependent and can be confounded by healthcare-seeking behavior.
Accuracy of HZ Diagnosis
To examine the accuracy of clinically diagnosed HZ, we compared the percentage of positive polymerase chain reaction (PCR) results between vaccinated and unvaccinated cases for whom HZ was diagnosed at clinics affiliated with Kaiser Permanente Southern California. Around 85% of the cases with clinically diagnosed HZ who underwent PCR had skin specimens that tested positive for HZ, and the results were very similar between the vaccinated and unvaccinated groups [25] . The caveat to this finding was that although the rate of PCR positivity among cases with clinically diagnosed HZ was similar between the vaccinated and unvaccinated groups, it is still unknown whether HZ vaccination leads to modified or atypical HZ presentations that are more likely to be underdiagnosed or misdiagnosed. If these cases are never diagnosed or are diagnosed as other conditions, they will not be identified through typical methods, such as by disease codes. This would lead to a potential over-estimation of VE. This becomes less of a concern if we define the outcome of interest to be HZ diagnoses that are clinically important.
Vaccination Selection or Preference
Another consideration is vaccination selection or vaccination preference, either by providers or by recipients. Physicians may be more likely to recommend certain vaccines to specific groups of patients that they perceive to be at higher risk for HZ. For example, persons anticipating immunosuppression are recommended to receive the HZ vaccine. This would certainly generate bias if the vaccinated group includes persons who are about to become immunosuppressed. This can be dealt with by excluding these subjects from the study or by modeling the timing of becoming immunosuppressed. However, immunosuppression is a vague term. The level at which immunosuppression could affect the risk of HZ is unknown. It becomes even more complicated when immunosuppression is measured by selected disease codes or medications, as commonly done in most health insurance claims-based or EHR studies. Defining and measuring immunosuppression will continue to be important issues for studying the VE of RZV.
Understanding Variation in Findings
Evaluating sources for variation among observational studies is critical to the appraisal of the study findings. Methodological differences can have a significant impact on VE estimation and interpretation of results. Major sources of variation include subject selection (eg, age, sex, and racial composition), HZ case definition and identification (eg, by disease codes only or by disease codes plus medication records), covariate measurement and adjustment (eg, measurement and control for immunosuppression), statistical modeling (eg, control for time-varying confounding), and cohort retention and follow-up duration.
Sources of Data
Two common data sources available for large-scale VE studies of HZ vaccine include EHR and health insurance claims-based data, such as Medicare data or private insurance claims data. Health insurance claims-based data provide opportunities for conducting large-scale retrospective VE studies. However, obtaining medical records for validation or confirmation requires additional effort or is infeasible. On the other hand, by using EHR data, both retrospective and prospective VE studies are feasible. There are other advantages of EHR data. For example, the case identification algorithm can combine information from diagnostic codes, laboratory test results, and medication records, and the history of HZ or recurrent episodes of HZ can be reviewed. Symptom onset and duration (eg, HZ-related pain) can be assessed through chart review.
We have used the Kaiser Permanente Southern California EHR system to identify HZ cases in real-time for a prospective study [25, 26] . Once a patient received a diagnosis with HZ and data were entered in the EHR, the information was retrieved immediately. We were able to recruit the patient into the study and obtain a specimen in time for PCR testing and then initiate follow-up the assess disease progression. This system was efficient for case identification, especially among vaccinated patients, for whom the incidence of HZ is lower. If RZV offers a level of protection similar to that found in RCTs, vaccinated patients with HZ will be even rarer. Our EHR system offers the ability to identify and recruit HZ patients efficiently.
HZ ophthalmicus (HZO) and PHN are usually undercoded, and the algorithms based on diagnostic codes have not been ideal [27] . With the availability of clinical notes in the EHR system, we have used natural language processing (NLP), instead of relying on codes, to identify patients with HZO. Compared with chart-reviewed results, the NLP algorithm can achieve 95.6% sensitivity and 99.3% specificity in identifying HZO cases. This approach allows the efficient evaluation of VE against HZO, a condition that is concerning to the elderly population [28] . NLP could potentially be used to efficiently identify PHN on the basis of clinical notes.
Future Studies When RZV Becomes Available
With licensure of RZV, many questions remain to be answered. Postlicensure research questions include the effectiveness and duration of protection for 1 or 2 doses of RZV at various intervals; the effectiveness of RZV in specific populations, such as immunosuppressed individuals, people with a history of HZ, and people who have received zoster vaccine live; the effectiveness of vaccination with RZV at various intervals after receiving zoster vaccine live; the effectiveness of RZV against PHN, HZO, or other complications; and the effectiveness of RZV when given concomitantly with other adult vaccines, such as influenza vaccine, pneumococcal conjugate vaccine, pneumococcal polysaccharide vaccine, or tetanus, diphtheria, and acellular pertussis vaccine. Since RZV has a new adjuvant and is being used in an older adult population, it will be critical to monitor its safety.
CONCLUSION
The use of real-world evidence with appropriate study designs and cautious interpretation can be informative in decision-making. Recent legislation in the 21st Century Cures Act and the Prescription Drug User Fee Act VI requires that the Food and Drug Administration use real-world evidence in regulatory decision-making [29, 30] .
As compared to RCTs, observational studies using real-world evidence have the advantage of larger, more inclusive populations and healthcare settings that reflect actual use in practice, with the ability to evaluate long-term duration of protection. We have highlighted considerations for conducting observational studies to evaluate VE for HZ vaccine. Understanding the advantages and limitations of studies that provide real-world evidence can equip us to critically evaluate findings from different studies.
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